Author:
Pallis A G,Voutsina A,Kalikaki Ar,Souglakos J,Briasoulis E,Murray S,Koutsopoulos A,Tripaki M,Stathopoulos E,Mavroudis D,Georgoulias V
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Altman GD (1991) Practical Statistics for Medical Research. London, UK: Chapman and Hall
2. Argiris A, Mittal N, Masters G (2003) Gefitinib (ZD1839) as first line, compassionate use therapy in patients with advanced NSCLC. Proc Am Soc Clin Oncol 22; Abstract 2729
3. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23: 8081–8092
4. Calvo E, Baselga J (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 24: 2158–2163
5. Carney DN (2002) Lung cancer – time to move on from chemotherapy. N Engl J Med 346: 126–128
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献